Linden Closes Acquisition of Majority Stake in Healthcare RCM Provider Aspirion.

MANews-(C)2009-2022

US-based private equity firm Linden Capital Partners has closed a majority investment in US-based healthcare revenue cycle management company Aspirion, the firm said.

Following the transaction, the company's management team and Aquiline Capital Partners, a private investment firm based in New York and London, will remain investors in the company.

Aspirion is a healthcare RCM provider across complex claims and revenue integrity, offering a range of technology-driven solutions for the most specialized revenue cycle challenges faced by hospital systems and healthcare providers.

The company's team of healthcare, legal, and technical professionals, in conjunction with its proprietary AI-enabled software, help hospitals and physicians improve claims processing time and increase overall collections.

Aspirion's product suite is centered on complex claims, an umbrella category for third party liability claims related to non-traditional payors, and revenue integrity, which addresses clinically complex claims with traditional medical payors.

Baird is serving as exclusive financial advisor and Ropes and Gray LLP is serving as legal counsel to Aquiline and Aspirion.

Guggenheim Securities, LLC and Cain Brothers, a division of KeyBanc Capital Markets Inc., are serving as financial advisors and Kirkland and Ellis LLP is serving as legal counsel to Linden.

Twin Brook Capital Partners is providing debt financing for the transaction.

Aspirion, headquartered in Columbus, Ga., helps hospitals and physicians recover otherwise lost claims revenue from Motor Vehicle Accidents, Workers' Compensation, Veterans Affairs, and TRICARE as well as out-of-state Medicaid, Medicaid eligibility, underpayments, and denials.

Aspirion's experienced team of healthcare, legal, and technical professionals...

To continue reading

Request your trial

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT